AI assistant
Sending…
AVADEL PHARMACEUTICALS PLC — Director's Dealing 2020
Aug 11, 2020
31920_dirs_2020-08-11_e328fd57-f234-44a6-8bb5-df1f81a039af.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2020-08-07
Reporting Person: Glass Geoffrey Michael (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-08-07 | Stock Option (Right to Buy) | $8.48 | A | 42000 | Acquired | 2020-08-07 | ADSs (42000) | Direct |
Footnotes
F1: Options become exercisable as to 14,000 ADSs on each of the first three anniversaries after the 08/07/2020 grant date.
F2: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by AmericanDepositary Receipts.
More from AVADEL PHARMACEUTICALS PLC
Regulatory Filings
2026
Feb 23
Director's Dealing
2026
Feb 18
Director's Dealing
2026
Feb 12
Director's Dealing
2026
Feb 12
Director's Dealing
2026
Feb 12
Director's Dealing
2026
Feb 12
Delisting Announcement
2026
Feb 12
Director's Dealing
2026
Feb 12
Director's Dealing
2026
Feb 12
Director's Dealing
2026
Feb 12